Private Placement

The biotech firm lands a major private placement, extending its cash runway to 2028 and signaling strong investor confidence in its novel drug platform.

With a new board chair, regulatory backing, and an AI platform, GC Therapeutics is targeting MS and diabetes with next-generation cell therapies.

Amid strong investor demand, VR Resources boosts its financing and plans a share consolidation to fuel its key copper, gold, and tungsten projects in Nevada.

Former mayoral candidate Luc Rabouin takes the helm at the $500M Foundation of Greater Montréal, bringing his urban development expertise to shape its future.

With its radical solar car on the line, Aptera appoints a VW and BMW veteran as Chairman. Can traditional auto expertise finally launch a new era of efficiency?

A 70-year-old infrastructure giant launches a new power company, aiming to redefine grid projects with an integrated, civil-first approach.

With a $200M facility, BlackOpal's GemStone uses blockchain to offer institutional investors high-yield Brazilian assets without the traditional credit risk.

MiNK Therapeutics and UW–Madison launch a trial for an 'off-the-shelf' cell therapy, aiming to prevent deadly Graft-Versus-Host Disease (GvHD).

Real estate icon Fredrik Eklund partners with co-ownership firm Pacaso. Is this the future of luxury property or just a new form of exclusivity?

A new campaign says indecision is the biggest business risk. Aily Labs' AI platform promises to end analysis paralysis and force confident, fast action.

With a new EV plant in Santa Teresa, GreenPower aims for market dominance while New Mexico pushes its ambitious clean energy and economic development goals.

A new class of painkillers promises the power of opioids with a far lower risk of addiction. Tris Pharma's cebranopadol could reshape pain management.

NeuroSense adds world-renowned expert Prof. Steven Arnold to its board, a major vote of confidence in its multi-target Alzheimer's drug, PrimeC.

The biotech firm launches an early access program for its novel platform, starting with a tau assay that could revolutionize Alzheimer's research.

With a major cash infusion and key pipeline milestones, Xilio Therapeutics validates its tumor-activated approach to fighting cancer and extends its runway to 2027.

A new national reimbursement code for NeurAxis's IB-Stim therapy is set to revolutionize access for chronic GI pain patients, validating the technology.

Collegium Pharmaceutical projects robust 2026 revenue fueled by its ADHD drug Jornay PM, savvy debt refinancing, and a proactive generic strategy.

A new vectorized antibody therapy for ALS, VTx-002, has been granted FDA Fast Track status, accelerating its path to patients battling the disease.

Eurythmics legend Dave Stewart launches a new venture builder to give artists control over their IP and revenue. But can this "creativity-first" model work?

How a blend of private capital and pragmatic regulation is turning Singapore into a global hub for longevity research, pushing scientific and ethical boundaries.